Hirth Peter 4

What Happened
Peter Hirth, a director of Aligos Therapeutics (ALGS), was granted an equity award on 2026-06-25 covering 5,860 shares. The grant is reported as a derivative acquisition with a $0.00 price (i.e., an option-style award granted as compensation rather than a cash purchase or open-market trade).

Key Details

• Transaction date: 2026-06-25; Form 4 filed: 2026-06-29 (filing within the standard two-business-day window).
• Reported transaction: Grant/award (derivative) for 5,860 shares, price shown $0.00.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The option vests and becomes exercisable 100% on the earlier of the first anniversary of the grant date or immediately prior to the Issuer’s 2027 annual meeting, subject to continuous service.
• No indication this was a sale or an open-market purchase; it is a compensatory grant.

Context
This is a compensation-related option grant to a director, which is common and does not by itself signal a personal open-market purchase or sale. For derivative awards like this, value realization depends on future vesting and exercise decisions; the filing does not show immediate sale or cashless exercise.